Patent intelligence · US
US 8138345
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
Patent details — US 8138345
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 20, 2012
- Expiration
- Mar 15, 2032
- Applicant
- Theravance, Inc.
- Claims
- 3
- CPC classes
- A61K, A61K31/444, A61K31/4709, A61K31/56
Quick answer
US 8138345 (Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity) is held by Theravance, Inc.. Status: granted. Granted Mar 20, 2012. Expires Mar 15, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K31/444, A61K31/4709, A61K31/56, A61K45/06, A61P
More from Theravance, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8138345?
US 8138345 (Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity) is held by Theravance, Inc.. Status: granted. Granted Mar 20, 2012. Expires Mar 15, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8138345?
Theravance, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8138345 expire?
Our index shows an expiration date of Mar 15, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.